- Home
- EEFT vs ACAD Comparison
EEFT vs ACAD Comparison
Compare EEFT & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EEFT
- ACAD
- Stock Information
- Founded
- EEFT 1994
- ACAD 1993
- Country
- EEFT United States
- ACAD United States
- Employees
- EEFT N/A
- ACAD N/A
- Industry
- EEFT EDP Services
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- EEFT Technology
- ACAD Health Care
- Exchange
- EEFT Nasdaq
- ACAD Nasdaq
- Market Cap
- EEFT 4.7B
- ACAD 4.0B
- IPO Year
- EEFT 1997
- ACAD 2004
- Fundamental
- Price
- EEFT $95.96
- ACAD $25.33
- Analyst Decision
- EEFT Buy
- ACAD Buy
- Analyst Count
- EEFT 6
- ACAD 20
- Target Price
- EEFT $123.83
- ACAD $28.63
- AVG Volume (30 Days)
- EEFT 700.4K
- ACAD 1.7M
- Earning Date
- EEFT 07-30-2025
- ACAD 08-06-2025
- Dividend Yield
- EEFT N/A
- ACAD N/A
- EPS Growth
- EEFT 26.28
- ACAD 615.00
- EPS
- EEFT 7.31
- ACAD 1.33
- Revenue
- EEFT $4,136,399,999.00
- ACAD $1,018,885,000.00
- Revenue This Year
- EEFT $10.58
- ACAD $13.28
- Revenue Next Year
- EEFT $8.09
- ACAD $10.88
- P/E Ratio
- EEFT $13.29
- ACAD $19.04
- Revenue Growth
- EEFT 8.71
- ACAD 14.41
- 52 Week Low
- EEFT $85.24
- ACAD $13.40
- 52 Week High
- EEFT $114.25
- ACAD $25.88
- Technical
- Relative Strength Index (RSI)
- EEFT 44.54
- ACAD 65.86
- Support Level
- EEFT $90.00
- ACAD $24.43
- Resistance Level
- EEFT $98.27
- ACAD $25.88
- Average True Range (ATR)
- EEFT 3.36
- ACAD 0.80
- MACD
- EEFT 0.30
- ACAD 0.09
- Stochastic Oscillator
- EEFT 37.58
- ACAD 84.20
About EEFT Euronet Worldwide Inc.
Euronet Worldwide Inc is a provider of electronic financial transaction solutions. It offers payment and transaction processing and distribution solutions to financial institutions, retailers, service providers, and individual consumers. The company's product offerings include comprehensive ATM, POS, card outsourcing, card issuing and merchant acquiring services, software solutions, money transfer services, etc. Its reportable operating segments are EFT Processing, epay, and Money Transfer. Maximum revenue is derived from its Money Transfer segment, which provides money transfer services across the world under the brand names Ria, AFEX, IME, and xe. Geographically, the company generates maximum revenue from the United States, followed by Germany, India, France, Greece, and other regions.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.